Evaluating the baseline survival outcomes of the "six Global Initiative for Childhood Cancer index cancers" in Africa

Limited survival data for the six Global Initiative for Childhood Cancer (GICC) priority cancers are available in Africa. Management of pediatric malignancies in Africa is challenging due to lack of resources, setting-specific comorbidities, high rates of late presentation and treatment abandonment....

Full description

Saved in:
Bibliographic Details
Published in:Pediatric hematology and oncology 2023-04, Vol.40 (3), p.203-223
Main Authors: van Heerden, Jaques, Balagadde-Kambugu, Joyce, Angom, Racheal, Lusobya, Rebecca Claire, Chantada, Guillermo, Desjardins, Laurence, Fabian, Ido Didi, Israels, Trijn, Paintsil, Vivian, Hessissen, Laila, Diouf, Mame Ndella, Elayadi, Moatasem, Turner, Suzanne D., Kouya, Francine, Geel, Jennifer A.
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Africa - epidemiology
Burkitt lymphoma
Child
Hodgkin lymphoma
Humans
Kidney Neoplasms
low-grade glioma
Neoplasms - epidemiology
Neoplasms - therapy
nephroblastoma
Retinal Neoplasms
Retinoblastoma
Wilms Tumor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Limited survival data for the six Global Initiative for Childhood Cancer (GICC) priority cancers are available in Africa. Management of pediatric malignancies in Africa is challenging due to lack of resources, setting-specific comorbidities, high rates of late presentation and treatment abandonment. Reporting of outcome data is problematic due to the lack of registries. With the aim of evaluating the feasibility of baseline outcomes for the six index cancers, we present a descriptive analysis of respective survival rates in Africa. The survival rates were between 18% (lower middle-income countries) to 82.3% (upper middle-income countries) for acute lymphoblastic leukemia, between 26.9% (low-income countries) to 77.9% (upper middle-income countries) for nephroblastoma, between 23% (low-income countries) to 100% (upper middle-income countries), for retinoblastoma, 45% (low-income countries) to 95% (upper middle-income countries) for Hodgkin lymphoma and 28% (low-income countries) to 76% (upper middle-income countries) for Burkitt lymphoma. Solutions to improve survival rates and reported outcomes include establishing and funding sustainable registries, training and to actively include all countries in consortia from different African regions.
ISSN:0888-0018
1521-0669
DOI:10.1080/08880018.2022.2140860